Clinical trials: Ototoxicity
Cisplatin Induced Hearing Loss
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of…
- Trial name
- NCT02997189
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Otonomy, Inc.